Dermira, Inc. (NASDAQ:DERM) – Analysts at Cantor Fitzgerald cut their FY2018 earnings per share estimates for shares of Dermira in a note issued to investors on Tuesday. Cantor Fitzgerald analyst L. Chen now forecasts that the biopharmaceutical company will post earnings of ($4.59) per share for the year, down from their previous estimate of ($4.45). Cantor Fitzgerald has a “Buy” rating and a $45.00 price objective on the stock.

COPYRIGHT VIOLATION WARNING: This news story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/fy2018-earnings-forecast-for-dermira-inc-issued-by-cantor-fitzgerald-derm/1697817.html.

Other research analysts also recently issued reports about the company. Leerink Swann reiterated an “outperform” rating and issued a $41.00 price target (down from $47.00) on shares of Dermira in a report on Tuesday, November 7th. Mizuho reissued a “buy” rating and set a $43.00 price objective (up from $40.00) on shares of Dermira in a research note on Thursday, September 7th. BidaskClub raised shares of Dermira from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 16th. Zacks Investment Research cut shares of Dermira from a “hold” rating to a “sell” rating in a research note on Thursday. Finally, Needham & Company LLC reissued a “buy” rating and set a $43.00 price objective (down from $46.00) on shares of Dermira in a research note on Tuesday, November 7th. Five analysts have rated the stock with a sell rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $43.33.

Dermira (NASDAQ:DERM) opened at $24.81 on Friday. The company has a quick ratio of 24.43, a current ratio of 4.68 and a debt-to-equity ratio of 1.40. Dermira has a twelve month low of $21.35 and a twelve month high of $38.75.

In related news, CEO Thomas G. Wiggans sold 5,000 shares of the company’s stock in a transaction on Tuesday, October 10th. The shares were sold at an average price of $27.52, for a total transaction of $137,600.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Eugene A. Bauer sold 7,500 shares of the company’s stock in a transaction on Wednesday, October 11th. The stock was sold at an average price of $30.04, for a total transaction of $225,300.00. The disclosure for this sale can be found here. Insiders have sold a total of 29,400 shares of company stock valued at $822,553 over the last three months. Corporate insiders own 13.30% of the company’s stock.

A number of institutional investors have recently made changes to their positions in DERM. Ameriprise Financial Inc. purchased a new stake in Dermira during the 1st quarter worth $1,170,000. Parametric Portfolio Associates LLC boosted its position in Dermira by 27.6% during the 1st quarter. Parametric Portfolio Associates LLC now owns 20,431 shares of the biopharmaceutical company’s stock worth $697,000 after purchasing an additional 4,417 shares during the period. Alliancebernstein L.P. boosted its position in Dermira by 4.5% during the 1st quarter. Alliancebernstein L.P. now owns 41,600 shares of the biopharmaceutical company’s stock worth $1,419,000 after purchasing an additional 1,800 shares during the period. TIAA CREF Investment Management LLC boosted its position in Dermira by 16.4% during the 1st quarter. TIAA CREF Investment Management LLC now owns 111,102 shares of the biopharmaceutical company’s stock worth $3,790,000 after purchasing an additional 15,678 shares during the period. Finally, Legal & General Group Plc boosted its position in Dermira by 16.3% during the 1st quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock worth $236,000 after purchasing an additional 963 shares during the period. 97.89% of the stock is owned by hedge funds and other institutional investors.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Earnings History and Estimates for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.